Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
VENT-02 provided full target coverage with a single dose No dose-limiting toxicities or serious adverse events observed Initiation of clinical trials in CNS diseases expected beginning in the second half of 2024 WALTHAM, Mass. & MONTREAL, April 17, 2024 BUSINESS WIRE Ventus Therapeutics , a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVE ™ , to develop differentiated small molecule therapeutics, today announced results from its Phase 1 clinical trial of VENT-02, a novel, oral, brain-penetrant NLRP3 inhibitor. The Phase 1 trial evaluated the pharmacodynamics, pharmacokinetics, safety, and tolerability of VENT-02 across a broad range of single and multiple ascending doses in adult healthy volunteers. "We are pleased with the results of this trial in which VENT-02 demonstrated a broad therapeutic index and complete target coverage, underscoring its potential to treat diseases of the CNS as well a
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Lilly Raises 2024 Guidance as Zepbound Keeps Flying Off Shelves [BNN Bloomberg (Canada)]BNN Bloomberg
- Chasing Novo and Lilly: The obesity drugs that could challenge Wegovy and Zepbound [Yahoo! Finance]Yahoo! Finance
- How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk [Yahoo! Finance]Yahoo! Finance
- Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings? [Yahoo! Finance]Yahoo! Finance
- UPDATE 1-One dose of Novo Nordisk's Wegovy back in supply, FDA website shows [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/3/23 - Beat
NVO
Sec Filings
- 4/26/24 - Form 6-K
- 4/25/24 - Form 6-K
- 4/25/24 - Form 6-K
- NVO's page on the SEC website